Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We employ our advanced, specialised process to create targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.
Key features that set our library apart include:
partner
Reaxense
upacc
Q17RR3
UPID:
LIPR3_HUMAN
Alternative names:
-
Alternative UPACC:
Q17RR3
Background:
Pancreatic lipase-related protein 3, encoded by the gene with the accession number Q17RR3, plays a crucial role in lipid metabolism. This enzyme is part of the lipase family, which is essential for the digestion and absorption of dietary fats in the gastrointestinal tract. Its specific functions and interactions within the lipid metabolism pathways highlight its importance in maintaining lipid homeostasis.
Therapeutic significance:
Understanding the role of Pancreatic lipase-related protein 3 could open doors to potential therapeutic strategies. Its pivotal role in lipid metabolism makes it a potential target for addressing disorders related to lipid digestion and absorption. Investigating this protein further could lead to breakthroughs in treating metabolic diseases.